What is Sixfold Bioscience?
Sixfold Bioscience is a preclinical-stage biotechnology company headquartered in London, focused on pioneering nucleic acid-based drug delivery systems. The company's core technology targets Cell & Gene therapeutics, with applications in short interfering RNA for gene silencing and messenger RNA for gene expression. This innovative approach positions Sixfold at the forefront of next-generation therapeutic development, addressing critical needs in genetic medicine.
How much funding has Sixfold Bioscience raised?
Sixfold Bioscience has raised a total of $10.5M across 1 funding round:
Angel/Seed
$10.5M
Angel/Seed (2021): $10.5M with participation from Y Combinator, Pi Campus, Cantos Ventures, and Lombardstreet Ventures
Key Investors in Sixfold Bioscience
Y Combinator
Y Combinator is a renowned accelerator program that provides seed funding and mentorship to early-stage startups, helping them scale and achieve significant growth.
Pi Campus
Pi Campus is a venture capital firm and startup district based in Rome that focuses on investing in early-stage startups, particularly those applying artificial intelligence to solve significant challenges in traditional industries.
Cantos Ventures
Cantos Ventures focuses on investing in near frontier technology that aims to tackle some of the world's largest challenges, supporting technical founders and science-forward enterprises in fields like energy, aerospace, biomanufacturing, and digital health.
What's next for Sixfold Bioscience?
The substantial enterprise-level funding Sixfold Bioscience has attracted indicates a strong market confidence in its technological platform and therapeutic pipeline. This capital infusion is expected to accelerate the company's preclinical development, advance its lead programs towards clinical trials, and potentially expand its research into new therapeutic areas. The strategic nature of the recent investment suggests a focus on scaling operations and forging key partnerships to bring its innovative drug delivery solutions to market.
See full Sixfold Bioscience company page
